Salvage therapy with azacitidine for pediatric acute myeloid leukemia with t(16;21)(p11;q22)/FUS‐ERG and early relapse after allogeneic blood stem cell transplantation: A case report

Acute myeloid leukemia (AML) with FUS‐ERG has a poor prognosis regardless of allo‐hematopoietic stem cell transplantation (HSCT). Maintenance therapy such as azacitidine after allo‐HSCT for AML with FUS‐ERG may be clinically meaningful.

Detalles Bibliográficos
Autores principales: Keino, Dai, Mori, Takashi, Morimoto, Mizuho, Kondo, Kensuke, Mori, Tetsuya, Kinoshita, Akitoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6878075/
https://www.ncbi.nlm.nih.gov/pubmed/31788268
http://dx.doi.org/10.1002/ccr3.2461

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6878075/
https://www.ncbi.nlm.nih.gov/pubmed/31788268
http://dx.doi.org/10.1002/ccr3.2461

Ejemplares similares